SCHEMBL2897506

SCHEMBL2897506

NCCC(=O)NCCC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 1/20 0.56
TSHR P16473 4/20 0.44
LMNA P02545 4/20 0.44
THRB P10828 2/20 0.44
BLM P54132 2/20 0.44
KMT2A Q03164 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
GABRR3 A8MPY1 1/20 0.44
GABRP O00591 1/20 0.44
GABRD O14764 1/20 0.44
HDAC3 O15379 1/20 0.44
GABBR2 O75899 1/20 0.44
CYP1A2 P05177 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRR1 P24046 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRR2 P28476 1/20 0.44
SLC6A1 P30531 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30526142 0.98 ECE1 (0.54) ECE1TSHRLMNATHRBBLM
SCHEMBL13788601 0.98 ECE1 (0.54) ECE1TSHRLMNATHRBBLM
SCHEMBL18571198 0.86 LMNA (0.58) ECE1TSHRLMNATHRBBLM
SCHEMBL1769661 0.86 ATM (0.55) TSHRLMNATHRBBLMKMT2A
SCHEMBL9717431 0.85 ECE1 (0.65) ECE1LMNAITGB3ITGA2BFAAH
SCHEMBL13788598 0.85 PRMT1 (0.57) TSHRLMNATHRBBLMKMT2A
SCHEMBL385127 0.83 ECE1 (0.58) ECE1TSHRLMNATHRBBLM
SCHEMBL20663420 0.83 PRMT1 (0.61) TSHRLMNATHRBBLMKMT2A
SCHEMBL26869544 0.83 PRMT1 (0.61) TSHRLMNATHRBBLMKMT2A
SCHEMBL18250764 0.83 LMNA (0.61) ECE1TSHRLMNATHRBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115057790-B Method for recovering 3-aminopropionic acid from 3-aminopropionic acid waste liquid 杭州鑫富科技有限公司 2024-05-28 CN claimed
CN-115057790-A Method for recovering 3-aminopropionic acid from 3-aminopropionic acid waste liquid 杭州鑫富科技有限公司 2022-09-16 CN claimed
EP-1313703-B1 PRODRUGS TO NMDA RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2008-02-13 EP claimed
CN-1227230-C Prodrugs to NMDA receptor ligands HOFFMANN LA ROCHE (CH) 2005-11-16 CN claimed
CN-1447793-A Prodrugs to NMDA receptor ligands HOFFMANN LA ROCHE (CH) 2003-10-08 CN claimed
US-6407235-B1 A NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR-SUBTYPE SELECTIVE BLOCKERS; PRODRUGS HAVE IMPROVED SOLUBILITY AND ARE HYDROLYZED IN VIVO; FOR EXAMPLE, THE 4-AMINOMETHYL-BENZOIC ACID ESTER OF THE PHENOL, OR THE PHOSPHATE ESTER HOFFMANN-LA ROCHE INC. 2002-06-18 US claimed
US-20020040037-A1 Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol EVOTEC INTERNATIONAL GMBH (DE) 2002-04-04 US claimed
EP-3650464-B1 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND SHANGPHARMA INNOVATION INC (US) 2025-11-05 EP disclosed
WO-2025222300-A1 ATRIAL NATRIURETIC PEPTIDE CONSTRUCTS FOR TARGETED PAYLOAD DELIVERY TO NPR-C EXPRESSING CELLS PROTEINQURE INC. (CA) 2025-10-30 WO disclosed
CN-120136965-A Isolated polypeptide of targeted MPP8 protein and application thereof 苏州系统医学研究所 2025-06-13 CN disclosed
EP-4554959-A2 COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE Pep2Tango Therapeutics Inc. (US) 2025-05-21 EP disclosed
CN-115057790-B Method for recovering 3-aminopropionic acid from 3-aminopropionic acid waste liquid 杭州鑫富科技有限公司 2024-05-28 CN disclosed
CN-115057790-B Method for recovering 3-aminopropionic acid from 3-aminopropionic acid waste liquid 杭州鑫富科技有限公司 2024-05-28 CN disclosed
WO-2002016321-A1 PRODRUGS TO NMDA RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2002-02-28 WO disclosed
US-5965106-A ADMINISTERING TARGETING MOIETY COUPLED TO AFFINITY COMPONENT, WHEREIN TARGETING MOIETY HAS AFFINITY FOR BINDING SITES IN TARGET AREA, AND BINDING PARTNER TO AFFINITY COMPONENT COUPLED TO FUNCTIONAL MOIETY TO LOCALIZE FUNCTIONAL MOIETY IN TARGET PERIMMUNE HOLDINGS, INC. (US) 1999-10-12 US disclosed
EP-0220245-B1 METHOD FOR DETERMINING MIMOTOPES COSELCO MIMOTOPES PTY. LTD. (AU) 1992-07-08 EP disclosed
US-4833092-A Method for determining mimotopes COMMONWEALTH SERUM LABORATORIES COMMISSION (AU) 1989-05-23 US disclosed
EP-0220245-A4 METHOD FOR DETERMINING MIMOTOPES. COMMW SERUM LAB COMMISSION (AU) 1988-01-26 EP disclosed
EP-0220245-A1 METHOD FOR DETERMINING MIMOTOPES. COMMW SERUM LAB COMMISSION (AU) 1987-05-06 EP disclosed
WO-1986006487-A1 METHOD FOR DETERMINING MIMOTOPES COMMONWEALTH SERUM LABORATORIES COMMISSION (AU) 1986-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040037-A1 Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol HAO2, CYP2B6, CBR1 ECE1 822/4885TSHR 2233/4885LMNA 4084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.